NHS Digital Data Release Register - reformatted

Iqvia Technology Services Ltd. projects

6 data files in total were disseminated unsafely (information about files used safely is missing for TRE/"system access" projects).

HES data for IQVIA clinical trial site identification — DARS-NIC-210151-K9C7G

Opt outs honoured: Anonymised - ICO Code Compliant (Does not include the flow of confidential data)

Legal basis: Health and Social Care Act 2012 – s261(1) and s261(2)(b)(ii), Health and Social Care Act 2012 - s261 - 'Other dissemination of information'

Purposes: (Supplier)

Sensitive: Non-Sensitive

When:DSA runs 2019-12-06 — 2020-12-05

Access method: Ongoing


Sublicensing allowed: No


  1. Hospital Episode Statistics Accident and Emergency
  2. Hospital Episode Statistics Admitted Patient Care
  3. Hospital Episode Statistics Outpatients
  4. Emergency Care Data Set (ECDS)

Yielded Benefits:

Clinical trials are often multi-year projects for which results are only available at the end of the research study. As such, it is too early to gauge the full impact of HES data on the trials that have been supported over the last year. This issue is compounded by many initial steps that are required even before running a trial, such as planning, protocol reviews, site selection, start-up and enrolment. However, as of September 30th 2019, IQVIA is currently running 13 ongoing trials that have used HES data; 7 are in the planning/start-up phase and 6 are enrolling patients. Of these trials, three are in rare diseases, two in oncology, and 14 patients have been enrolled. Without access to this data, it would not have been possible to enrol these patients into clinical trials in these difficult-to-treat and difficult-to-identify diseases. This has also enabled patients to receive cutting-edge therapies far sooner than would ordinarily be possible.

Expected Benefits:

CTSI projects and CTSI Outputs based on HES data are expected to generate benefits to UK healthcare by:

• accelerating study start-up through faster site identification and patient recruitment into clinical trials, which in turn will assist in improving patient access to treatments under development, especially for diseases that are rare and/or difficult to treat. IQVIA work across all major disease areas including cardiovascular diseases, oncology, pediatric indications, and many other less common indications.
• reducing the proportion of unsuccessful clinical trials, which could facilitate the approval and availability of potentially life changing medicines to patients in the UK
• reducing the cost of clinical trials, which could translate into reduced costs to manufacturers in developing new medicines and reduced costs to the NHS in procuring new medicines
• promoting the UK and the NHS as suitable for conducting clinical trials, which supports the evaluation and approval by UK and European Union-based regulatory bodies of medicines and treatments under development


As stated under “Processing Activities", Relevant Extracts from an Appropriate Software Tool will be used for CTSI, the outputs of which shall consist of a list of hospital sites with estimates of the size of the patient population at those sites, a list of physicians affiliated with those sites (based on IQVIA group internal physician data), and visualisations of the CTSI Analysis; all of these outputs together shall comprise the “CTSI Outputs". The CTSI Outputs shall be produced to meet the previously stated purpose. Outputs will only contain aggregate level data with small numbers suppressed in line with the HES analysis guide, or estimates of patient numbers that are based on such aggregated and small number suppressed data.

CTSI Outputs shall occasionally be reported in journal articles or conference presentations. Examples of relevant industry conferences where CTSI Outputs may be reported include the International Society for Pharmacoeconomics and Outcomes Research (ISPOR) and the Drug Information Association (DIA) conferences.